ATE372784T1 - Rekombinante proteine, die epitope des humanen papillomavirus inseriert in einem adenylatecyclase protein oder in dessen fragmenten tragen, und deren terapeutischen verwendung. - Google Patents

Rekombinante proteine, die epitope des humanen papillomavirus inseriert in einem adenylatecyclase protein oder in dessen fragmenten tragen, und deren terapeutischen verwendung.

Info

Publication number
ATE372784T1
ATE372784T1 AT04290741T AT04290741T ATE372784T1 AT E372784 T1 ATE372784 T1 AT E372784T1 AT 04290741 T AT04290741 T AT 04290741T AT 04290741 T AT04290741 T AT 04290741T AT E372784 T1 ATE372784 T1 AT E372784T1
Authority
AT
Austria
Prior art keywords
protein
adenylatecyclase
terapeutic
fragments
recombinant proteins
Prior art date
Application number
AT04290741T
Other languages
English (en)
Inventor
Xavier-Edmond-Edouard Preville
Claude Leclerc
Daniel Ladant
Benedikt Timmerman
Original Assignee
Pasteur Institut
Bt Pharma
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Bt Pharma, Inst Nat Sante Rech Med, Centre Nat Rech Scient filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE372784T1 publication Critical patent/ATE372784T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT04290741T 2004-03-18 2004-03-18 Rekombinante proteine, die epitope des humanen papillomavirus inseriert in einem adenylatecyclase protein oder in dessen fragmenten tragen, und deren terapeutischen verwendung. ATE372784T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04290741A EP1576967B1 (de) 2004-03-18 2004-03-18 Rekombinante Proteine, die Epitope des humanen Papillomavirus inseriert in einem Adenylatecyclase Protein oder in dessen Fragmenten tragen, und deren terapeutischen Verwendung.

Publications (1)

Publication Number Publication Date
ATE372784T1 true ATE372784T1 (de) 2007-09-15

Family

ID=34833798

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04290741T ATE372784T1 (de) 2004-03-18 2004-03-18 Rekombinante proteine, die epitope des humanen papillomavirus inseriert in einem adenylatecyclase protein oder in dessen fragmenten tragen, und deren terapeutischen verwendung.

Country Status (19)

Country Link
US (3) US8628779B2 (de)
EP (3) EP1576967B1 (de)
JP (2) JP5438897B2 (de)
KR (2) KR101495740B1 (de)
CN (1) CN1956730B (de)
AT (1) ATE372784T1 (de)
AU (1) AU2005224036B2 (de)
BR (1) BRPI0508722A (de)
CA (1) CA2559235C (de)
CY (1) CY1107042T1 (de)
DE (1) DE602004008874T2 (de)
DK (1) DK1576967T3 (de)
ES (1) ES2293178T3 (de)
MX (1) MXPA06010469A (de)
PL (1) PL1576967T3 (de)
PT (1) PT1576967E (de)
RU (1) RU2441022C2 (de)
SI (1) SI1576967T1 (de)
WO (1) WO2005089792A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE438409T1 (de) 2000-09-15 2009-08-15 Pasteur Institut Proteinhaltigen vektoren zur einführung von moleküle in cd11b exprimirende zellen
SI1576967T1 (sl) 2004-03-18 2008-02-29 Pasteur Institut Rekombinantni protein, ki nosi epitope humanega papilomavirusa, vstavljene v adenilat ciklazni protein ali njegov fragment, in njegove terapevtske uporabe
EP2656842B1 (de) * 2006-03-27 2016-08-10 The Regents of The University of California Androgenrezeptor-modulator zur behandlung von prostatakrebs und androgenrezeptor-assoziierte erkrankungen
EP1894941A1 (de) * 2006-09-01 2008-03-05 Institut Pasteur Behandlung von Gebärmutterhalskarzinomen mit einer rekombinanten Adenylat-Cyclase die HPV-Antigene trägt
TWI423814B (zh) * 2006-09-01 2014-01-21 Genticel 用於引發特異性細胞毒性ｔ淋巴細胞（ｃｔｌ）反應之組成物，包含一淋巴去除性化合物以及一含有抗原序列且以專業化抗原呈現細胞為標靶之分子
EP2468763B1 (de) * 2007-05-31 2014-06-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC HPV-Epitope als Ziel für zervikale Tumoren infiltrierende T-Zellen zur Verwendung bei Impfstoffen
ES2331271B1 (es) * 2007-06-29 2010-10-14 Universidad Del Pais Vasco Metodo para la internalizacion de bacterias no invasivas en celulas eucariotas.
AU2008280436A1 (en) * 2007-07-24 2009-01-29 Stichting Katholieke Universiteit Radboud University Nijmegen Medical Centre Compositions and methods for generating an immune response in a subject
CN105602924A (zh) * 2009-03-23 2016-05-25 巴斯德研究院 适合将免疫原性分子递送到细胞中的突变CyaA多肽及多肽衍生物
JP5964233B2 (ja) * 2009-09-11 2016-08-03 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダＰｒｏｙｅｃｔｏ Ｄｅ Ｂｉｏｍｅｄｉｃｉｎａ Ｃｉｍａ， Ｓ．Ｌ． Ｈｐｖにより惹起される疾患の治療用組成物
JP5964298B2 (ja) * 2010-07-15 2016-08-03 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ ヒトパピローマウイルスｅ７抗原組成物およびその使用
EP2478915A1 (de) * 2011-01-24 2012-07-25 Genticel cyaA-getragene Polypeptid(e) und Verwendung zur Induzierung von therapeutischen und prophylaktischen Immunantworten
ES2670095T3 (es) 2011-06-17 2018-05-29 Universiteit Gent Vacunas contra Chlamydia
CA2858963C (en) * 2011-12-21 2023-05-23 Vaccibody As Vaccines against hpv
EP2687849A1 (de) * 2012-07-20 2014-01-22 ISA Pharmaceuticals B.V Verfahren zur Bereitstellung einer optimierten Immuntherapiezusammensetzung
EP2689786A1 (de) 2012-07-23 2014-01-29 Genticel HPV/CYAA-basierte chimäre Proteine und deren Verwendungen bei der Induktion von Immunreaktionen gegen eine HPV-Infektion und HPV-induzierter Störungen
EP2690172A1 (de) 2012-07-23 2014-01-29 Genticel CYAA-basierte chimäre Proteine mit einem heterologen Polypeptid und deren Verwendungen bei der Induktion von Immunreaktionen
WO2015018943A2 (en) * 2013-08-08 2015-02-12 Institut Pasteur Correlation of disease activity with clonal expansions of human papillomavirus 16-specific cd8+ t-cells in patients with severe erosive oral lichen planus
EP2975120A1 (de) 2014-07-17 2016-01-20 Institut Pasteur Monomeres und funktionelles Adenylatcyclase-CyaA-Toxin
US10420826B2 (en) 2014-11-11 2019-09-24 Massachusetts Eye & Ear Infirmary Conjunctivitis vaccines
EP3037103A1 (de) 2014-12-23 2016-06-29 Genticel Immunotherapeutischer Impfstoff mit E7-Proteinen von HPV16 und HPV18 fusioniert mit CyaA zur Verwendung bei mit HIV infizierten Personen
KR102668219B1 (ko) 2015-03-16 2024-05-28 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Mhc 세포 라이브러리를 이용하여 신규한 면역원성 t 세포 에피토프를 검출하고 신규한 항원-특이적 t 세포 수용체를 단리하는 방법
AU2017205270B2 (en) 2016-01-08 2024-01-18 Nykode Therapeutics ASA Therapeutic anticancer neoepitope vaccine
WO2017211886A1 (en) * 2016-06-07 2017-12-14 Deutsches Krebsforschungszentrum Improvement of hpv l2 peptide immunogenicity
WO2018091613A1 (en) 2016-11-17 2018-05-24 Ecole Nationale Vétérinaire de Toulouse Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection
EP3323426A1 (de) 2016-11-17 2018-05-23 Ecole Nationale Vétérinaire de Toulouse Immunogen- und impfstoffzusammensetzungen zur verwendung gegen bordetella-bronchiseptica-infektion
EP3342421A1 (de) 2016-12-27 2018-07-04 Genticel Immunogene zusammensetzung mit cyaa-abgeleitetem polypeptid, das eine th1/th17-orientierte immunreaktion fördert
CN112423783A (zh) * 2018-05-30 2021-02-26 德国癌症研究中心 组合的预防性和治疗性疫苗
WO2021063917A1 (en) 2019-10-01 2021-04-08 Universiteit Gent Vaccine against chlamydia in swine
CN121487960A (zh) * 2023-04-30 2026-02-06 布坦坦研究院 重组蛋白、表达盒、免疫原性组合物及其用途
CN117777313B (zh) * 2024-01-11 2026-03-20 杭州斯达特生物科技有限公司 His-SUMO标签在制备重组HPV18 E7蛋白中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015044A1 (de) * 1990-05-10 1991-11-14 Behringwerke Ag Seroreaktive epitope auf proteinen des menschlichen papillomavirus (hpv) 18
SE9001705D0 (sv) * 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
US6183745B1 (en) * 1990-12-12 2001-02-06 The University Of Queensland Subunit papilloma virus vaccine and peptides for use therein
CA2133999A1 (en) * 1992-04-21 1993-10-28 Daniel Ladant Recombinant mutants for inducing specific immune responses
GB9621091D0 (en) * 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ATE438409T1 (de) 2000-09-15 2009-08-15 Pasteur Institut Proteinhaltigen vektoren zur einführung von moleküle in cd11b exprimirende zellen
AU2002327338A1 (en) * 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
EP1489092A1 (de) 2003-06-18 2004-12-22 Institut Pasteur Modifizierte Bordetella Adenylatcyclase mit oder ohne CD11b/CD18 Interaktionsdomäne und seine Verwendungen
CA2546452C (en) * 2003-11-21 2015-01-20 Institut Pasteur Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens
SI1576967T1 (sl) 2004-03-18 2008-02-29 Pasteur Institut Rekombinantni protein, ki nosi epitope humanega papilomavirusa, vstavljene v adenilat ciklazni protein ali njegov fragment, in njegove terapevtske uporabe
EP1894941A1 (de) * 2006-09-01 2008-03-05 Institut Pasteur Behandlung von Gebärmutterhalskarzinomen mit einer rekombinanten Adenylat-Cyclase die HPV-Antigene trägt
PT2233569E (pt) 2009-03-23 2014-10-06 Pasteur Institut Polipéptidos mutantes de cyaa e derivados de polipéptidos adequados para a entrega de moléculas imunogénicas numa célula

Also Published As

Publication number Publication date
EP1725259A1 (de) 2006-11-29
JP5824474B2 (ja) 2015-11-25
EP1576967A1 (de) 2005-09-21
SI1576967T1 (sl) 2008-02-29
JP5438897B2 (ja) 2014-03-12
MXPA06010469A (es) 2007-07-04
CA2559235A1 (en) 2005-09-29
CN1956730B (zh) 2012-04-25
DK1576967T3 (da) 2008-01-21
EP2351580A1 (de) 2011-08-03
CA2559235C (en) 2015-06-16
PT1576967E (pt) 2007-12-03
AU2005224036B2 (en) 2011-10-20
KR20130079671A (ko) 2013-07-10
ES2293178T3 (es) 2008-03-16
JP2007533307A (ja) 2007-11-22
PL1576967T3 (pl) 2008-03-31
US9387243B2 (en) 2016-07-12
WO2005089792A1 (en) 2005-09-29
US20070072266A1 (en) 2007-03-29
US8637039B2 (en) 2014-01-28
KR101382250B1 (ko) 2014-04-24
RU2006131598A (ru) 2008-04-27
KR20070031889A (ko) 2007-03-20
US8628779B2 (en) 2014-01-14
EP1576967B1 (de) 2007-09-12
EP2351580B1 (de) 2017-09-20
AU2005224036A1 (en) 2005-09-29
RU2441022C2 (ru) 2012-01-27
KR101495740B1 (ko) 2015-02-25
EP1725259B1 (de) 2018-02-21
CN1956730A (zh) 2007-05-02
CY1107042T1 (el) 2012-09-26
US20140227308A1 (en) 2014-08-14
US20110171244A1 (en) 2011-07-14
DE602004008874T2 (de) 2008-06-12
JP2013176390A (ja) 2013-09-09
BRPI0508722A (pt) 2007-08-14
DE602004008874D1 (de) 2007-10-25

Similar Documents

Publication Publication Date Title
ATE372784T1 (de) Rekombinante proteine, die epitope des humanen papillomavirus inseriert in einem adenylatecyclase protein oder in dessen fragmenten tragen, und deren terapeutischen verwendung.
WO2008026071A3 (en) Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying hpv antigens
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
HUP0500345A2 (hu) Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
PT1383785E (pt) Anticorpo recombinante específico de tumores e utilização deste
DE602006021296D1 (de) Monoklonale antikörper und einzelkettenantikörper fragments gegen das zelloberflächen prostataspezifische membranantigen
GEP20105059B (en) Anti-cd154 antibodies
PH12022550056A1 (en) Dll3-targeting antibodies and uses thereof
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
BRPI0606790A2 (pt) anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna.
WO2021181233A3 (en) Cd80-fc fusion protein and uses thereof
GEP20105022B (en) Use of polypeptides of the cupredoxin family in cancer therapy
WO2005120166A3 (en) Antibodies for selective apoptosis of cells
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
MXPA05007940A (es) Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1.
EP2193804A3 (de) Rekombinantes Adenylat-Cyclase-Toxin von Bordetella induziert T-Zell-Antworten gegen tumorale Antigene
TW200716161A (en) Compositions and methods for treating or preventing overweight or obesity with zinc-charged protein fragments
ZA202106627B (en) Treatment of headache using anti-cgrp antibodies
PL1694697T3 (pl) Zlokalizowane na powierzchni polipeptydy campylobacter jejuni
MX2007003624A (es) Peptidos y derivados tipo peptido ligando alterado de la hsp60 y composiciones farmaceuticas.
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
GB0611708D0 (en) Novel antibodies against prion protein and uses thereof
MX2024009721A (es) Anticuerpos y fragmentos de anticuerpos y analogos especificos para sulfato de condroitina.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1576967

Country of ref document: EP

EEFA Change of the company name